Bb Biotech Ag Stock Net Income
| BION Stock | CHF 47.05 0.70 1.51% |
As of the 3rd of February, BB Biotech owns the Standard Deviation of 1.71, market risk adjusted performance of 1.06, and Coefficient Of Variation of 636.39. BB Biotech AG technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices. Please confirm BB Biotech AG semi deviation, coefficient of variation, and the relationship between the mean deviation and downside deviation to decide if BB Biotech AG is priced fairly, providing market reflects its prevailing price of 47.05 per share.
BB Biotech Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 9.8483 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 68.3 M | 64.9 M | |
| Net Income From Continuing Ops | 68.3 M | 64.9 M | |
| Net Income Applicable To Common Shares | 68.3 M | 64.9 M | |
| Net Income Per Share | 1.59 | 3.10 | |
| Net Income Per E B T | 0.90 | 0.80 |
BION | Net Income |
The evolution of Net Income for BB Biotech AG provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how BB Biotech compares to historical norms and industry peers.
Latest BB Biotech's Net Income Growth Pattern
Below is the plot of the Net Income of BB Biotech AG over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in BB Biotech AG financial statement analysis. It represents the amount of money remaining after all of BB Biotech AG operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is BB Biotech's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BB Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 75.9 M | 10 Years Trend |
|
Net Income |
| Timeline |
BION Net Income Regression Statistics
| Arithmetic Mean | 209,376,161 | |
| Geometric Mean | 323,719,848 | |
| Coefficient Of Variation | 280.18 | |
| Mean Deviation | 472,129,161 | |
| Median | 75,899,000 | |
| Standard Deviation | 586,634,253 | |
| Sample Variance | 344139.7T | |
| Range | 2.3B | |
| R-Value | (0.32) | |
| Mean Square Error | 330643T | |
| R-Squared | 0.1 | |
| Significance | 0.22 | |
| Slope | (36,601,682) | |
| Total Sum of Squares | 5506236T |
BION Net Income History
BION Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for BB Biotech is extremely important. It helps to project a fair market value of BION Stock properly, considering its historical fundamentals such as Net Income. Since BB Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BB Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BB Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
BB Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BB Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BB Biotech.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in BB Biotech on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding BB Biotech AG or generate 0.0% return on investment in BB Biotech over 90 days. BB Biotech is related to or competes with Idorsia, Tecan Group, Kuros Biosciences, Basilea Pharmaceutica, Evolva Holding, Santhera Pharmaceuticals, and Molecular Partners. BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG More
BB Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BB Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BB Biotech AG upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.78 | |||
| Information Ratio | 0.1245 | |||
| Maximum Drawdown | 9.03 | |||
| Value At Risk | (2.08) | |||
| Potential Upside | 2.98 |
BB Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BB Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BB Biotech's standard deviation. In reality, there are many statistical measures that can use BB Biotech historical prices to predict the future BB Biotech's volatility.| Risk Adjusted Performance | 0.1209 | |||
| Jensen Alpha | 0.247 | |||
| Total Risk Alpha | 0.1517 | |||
| Sortino Ratio | 0.1194 | |||
| Treynor Ratio | 1.05 |
BB Biotech February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1209 | |||
| Market Risk Adjusted Performance | 1.06 | |||
| Mean Deviation | 1.34 | |||
| Semi Deviation | 1.57 | |||
| Downside Deviation | 1.78 | |||
| Coefficient Of Variation | 636.39 | |||
| Standard Deviation | 1.71 | |||
| Variance | 2.92 | |||
| Information Ratio | 0.1245 | |||
| Jensen Alpha | 0.247 | |||
| Total Risk Alpha | 0.1517 | |||
| Sortino Ratio | 0.1194 | |||
| Treynor Ratio | 1.05 | |||
| Maximum Drawdown | 9.03 | |||
| Value At Risk | (2.08) | |||
| Potential Upside | 2.98 | |||
| Downside Variance | 3.17 | |||
| Semi Variance | 2.47 | |||
| Expected Short fall | (1.46) | |||
| Skewness | (0.56) | |||
| Kurtosis | 1.18 |
BB Biotech AG Backtested Returns
BB Biotech appears to be very steady, given 3 months investment horizon. BB Biotech AG retains Efficiency (Sharpe Ratio) of 0.15, which signifies that the company had a 0.15 % return per unit of price deviation over the last 3 months. We have found twenty-nine technical indicators for BB Biotech, which you can use to evaluate the volatility of the entity. Please makes use of BB Biotech's Coefficient Of Variation of 636.39, market risk adjusted performance of 1.06, and Standard Deviation of 1.71 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, BB Biotech holds a performance score of 11. The firm owns a Beta (Systematic Risk) of 0.25, which signifies not very significant fluctuations relative to the market. As returns on the market increase, BB Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding BB Biotech is expected to be smaller as well. Please check BB Biotech's semi deviation, coefficient of variation, and the relationship between the mean deviation and downside deviation , to make a quick decision on whether BB Biotech's current price history will revert.
Auto-correlation | 0.49 |
Average predictability
BB Biotech AG has average predictability. Overlapping area represents the amount of predictability between BB Biotech time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BB Biotech AG price movement. The serial correlation of 0.49 indicates that about 49.0% of current BB Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.49 | |
| Spearman Rank Test | 0.48 | |
| Residual Average | 0.0 | |
| Price Variance | 2.36 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, BB Biotech AG reported net income of 75.9 M. This is 77.76% lower than that of the Biotechnology sector and 8.36% higher than that of the Health Care industry. The net income for all Switzerland stocks is 86.71% higher than that of the company.
BION Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BB Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BB Biotech could also be used in its relative valuation, which is a method of valuing BB Biotech by comparing valuation metrics of similar companies.BB Biotech is currently under evaluation in net income category among its peers.
BB Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BB Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BB Biotech's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
BION Fundamentals
| Return On Equity | 0.0732 | ||||
| Return On Asset | 0.0453 | ||||
| Profit Margin | 0.82 % | ||||
| Operating Margin | 0.99 % | ||||
| Current Valuation | 2.2 B | ||||
| Shares Outstanding | 55.15 M | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 14.76 % | ||||
| Price To Earning | 23.12 X | ||||
| Price To Book | 1.11 X | ||||
| Price To Sales | 8.52 X | ||||
| Revenue | 111.63 M | ||||
| Gross Profit | 201.41 M | ||||
| EBITDA | 80.24 M | ||||
| Net Income | 75.9 M | ||||
| Cash And Equivalents | 458 K | ||||
| Cash Per Share | 65.76 X | ||||
| Total Debt | 117.5 M | ||||
| Debt To Equity | 11.30 % | ||||
| Current Ratio | 9.72 X | ||||
| Book Value Per Share | 41.83 X | ||||
| Cash Flow From Operations | 304.56 M | ||||
| Earnings Per Share | 3.02 X | ||||
| Target Price | 47.7 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 2.25 B | ||||
| Total Asset | 2.41 B | ||||
| Retained Earnings | 2.31 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 4.63 % | ||||
| Net Asset | 2.41 B | ||||
| Last Dividend Paid | 1.8 |
About BB Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BB Biotech AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BB Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BB Biotech AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BION Stock Analysis
When running BB Biotech's price analysis, check to measure BB Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BB Biotech is operating at the current time. Most of BB Biotech's value examination focuses on studying past and present price action to predict the probability of BB Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BB Biotech's price. Additionally, you may evaluate how the addition of BB Biotech to your portfolios can decrease your overall portfolio volatility.